Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tenaya TherapeuticsTNYA +3.29%32 PB Ratio is 2.44 as of Aug. 12, 2026, which is 45% above its 10-year median of 1.68. GuruFocus rates TNYA with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,222 Biotechnology companies, Tenaya Therapeutics ranks better than 57.77% on this metric.
The historical rank and industry rank for Tenaya Therapeutics's PB Ratio or its related term are showing as below:
TNYA'
s PB Ratio Range Over the Past 10 Years
Min: 1.37 Med: 1.68 Max: 2.73
Current: 2.43
During the past 7 years, Tenaya Therapeutics's highest PB Ratio was 2.73. The lowest was 1.37. And the median was 1.68.
TNYA's PB Ratio is ranked better than 57.77% of 1222
companies
in the Biotechnology industry
Industry Median: 2.92
vs TNYA: 2.43
During the past 12 months, Tenaya Therapeutics's average Book Value Per Share Growth Rate was -48.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -46.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Tenaya Therapeutics was -45.80% per year. The lowest was -46.10% per year. And the median was -45.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tenaya Therapeutics PB Ratio Related Terms
Tenaya Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Tenaya Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tenaya Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenaya Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Tenaya Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tenaya Therapeutics (TNYA) has a PB Ratio of 2.44 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tenaya Therapeutics and its competitors. This is 45% above median its historical median of 1.68. Over the past decade, Tenaya Therapeutics' PB Ratio has ranged from 1.37 to 2.73. According to the industry distribution chart, Tenaya Therapeutics ranks #516 out of 1222 companies in the Biotechnology industry, placing it in the top 42.2%.
Is Tenaya Therapeutics' PB Ratio too high?
Tenaya Therapeutics' current PB Ratio of 2.44 is 45% above median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 2.73. The Biotechnology industry median PB Ratio is 2.92. Tenaya Therapeutics' value of 2.44 is 16.4% below this industry median. Based on the distribution chart, Tenaya Therapeutics ranks #516 out of 1222 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tenaya Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tenaya Therapeutics' PB Ratio compare to KPTI and HUMA?
According to the Biotechnology industry distribution chart, Tenaya Therapeutics ranks #516 out of 1222 companies for PB Ratio. This puts Tenaya Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.92. Tenaya Therapeutics' value of 2.44 is 16.4% below this benchmark. Historically, Tenaya Therapeutics' own PB Ratio has ranged from 1.37 to 2.73 over the past decade. While the company's 10-year median is 1.68 vs. the industry median of 2.92, Tenaya Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,222 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenaya Therapeutics's current PB Ratio of 2.44 is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tenaya Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenaya Therapeutics's current PB Ratio is 2.44, which is 45% above median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenaya Therapeutics stock overvalued right now?
Tenaya Therapeutics (TNYA) has a current PB Ratio of 2.44. The current PB Ratio is 2.44, which is 45% above median its 10-year median of 1.68 and 16.4% below the Biotechnology industry median of 2.92. Tenaya Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tenaya Therapeutics (TNYA), the current PB Ratio is 2.44 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
32GF Score
Get the complete analysis for TNYA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNYA has been successfully added to your 
